| Key Takeaways: Both drugs cause similar GI side effects (nausea, diarrhoea, vomiting), but data from the SURMOUNT-5 trial suggest tirzepatide has slightly lower discontinuation rates due to GI intolerance (2.7% vs 5.6% for semaglutide). Most side effects peak during dose escalation and improve significantly once you stabilize at a maintenance dose. Both drugs carry the same class-wide boxed warning for thyroid C-cell tumours (seen in rodents). Rare but serious risks include pancreatitis, gallbladder disease, and acute kidney injury. |
If you have started one of these medications, or your doctor is weighing up the options, you probably want a straight answer: which one is harder on your body?
This guide walks through the side-effect data from the major Phase 3 trials, explains what the risks actually mean, and gives you practical strategies for managing the common symptoms.
1. What Are These Drugs, and Why Do They Cause Side Effects?
Semaglutide (Ozempic, Wegovy) is a GLP-1 receptor agonist. It mimics one gut hormone to slow gastric emptying, suppress appetite, and improve blood sugar control.
Tirzepatide (Mounjaro, Zepbound) is a dual GIP/GLP-1 receptor agonist. It activates two receptors simultaneously, which explains both its stronger efficacy and its somewhat different tolerability profile. For the deeper mechanism behind why tirzepatide outperforms GLP-1-only therapies, see our dedicated dual-agonist explainer.
The side effects both drugs produce stem directly from their mechanism. Slowing the stomach and amplifying the brain’s fullness signal are the same actions that reduce appetite and body weight. They are also the same actions that cause nausea.
GIP receptor activation (unique to tirzepatide) appears to partially modulate the GI effects of GLP-1 stimulation.
Some researchers believe this may explain why tirzepatide, despite producing more weight loss, can show comparable or slightly lower rates of nausea in direct comparisons.
| Feature | Semaglutide | Tirzepatide |
|---|---|---|
| Drug class | GLP-1 receptor agonist | Dual GIP/GLP-1 receptor agonist |
| Brand names (India) | Ozempic (diabetes), Wegovy (weight) | Mounjaro (diabetes); Zepbound under CDSCO review |
| Injection frequency | Once weekly | Once weekly |
| Max approved dose | 2.4 mg/week (weight management) | 15 mg/week |
| Regulatory status in India | Ozempic approved; Wegovy launch planned 2026 | Mounjaro CDSCO-approved for T2D (2024) |
2. The Stomach Stuff: How Common Are GI Side Effects?
This is where most people have concerns, and rightly so. Gastrointestinal symptoms are the most frequently reported adverse effects for both medications.
What the Phase 3 trials reported
In the STEP-1 trial (semaglutide 2.4 mg for weight management, NEJM 2021), nausea was the most commonly reported adverse event.
GI-related side effects caused treatment discontinuation in 4.5% of semaglutide participants, compared with 0.8% on placebo.
In SURMOUNT-1 (tirzepatide for weight management, NEJM 2022), nausea was reported in 24% to 33% of participants depending on dose, diarrhoea in 17% to 23%, constipation in 11% to 17%, and vomiting in 6% to 13%. These were primarily mild to moderate in severity.
The head-to-head verdict: SURMOUNT-5
The most direct comparison comes from the SURMOUNT-5 trial (NEJM 2025), the first Phase 3b study to compare tirzepatide and semaglutide head-to-head in 751 adults with obesity.
GI adverse events were the most common complaint in both groups, with most episodes being mild to moderate in severity.
The key tolerability finding: GI adverse events caused treatment discontinuation in 5.6% of the semaglutide group versus 2.7% in the tirzepatide group.
| GI Side Effect | Tirzepatide (SURMOUNT-1 range) | Semaglutide (STEP trials range) |
|---|---|---|
| Nausea | 24% to 33% | ~20% (weight management doses) |
| Diarrhoea | 17% to 23% | ~30% (reported in STEP-1 population) |
| Vomiting | 6% to 13% | ~9% (SURPASS-2 comparator data) |
| Constipation | 11% to 17% | ~11% (STEP-1 data) |
| Discontinuation (GI reason) | 2.7% (SURMOUNT-5) | 5.6% (SURMOUNT-5) |
Sources: SURMOUNT-1 NEJM 2022; SURMOUNT-5 ACC/NEJM 2025; STEP-1 NEJM 2021; Patel et al., Diabetes, Obesity and Metabolism 2024 (SURPASS trials pooled analysis, PMC; doi:10.1111/dom.15333).
An important nuance on the numbers
Trial populations and dose titration schedules differ between the STEP and SURMOUNT series.
A pooled meta-analysis of SURPASS-1 to SURPASS-5 trials (N = 6,263) published in the same journal found nausea, diarrhoea, and vomiting were transient and of mild-to-moderate severity across tirzepatide doses.
Importantly, patients who experienced GI symptoms still lost comparable amounts of weight to those who did not, which suggests the weight loss benefit is not primarily driven by nausea-induced calorie restriction.
3. Beyond the Stomach: Other Common Side Effects
Reduced appetite and fatigue
Both drugs substantially reduce appetite. A pooled analysis of SURPASS trials reported decreased appetite in approximately 9.6% of tirzepatide participants.
This is often experienced as a therapeutic benefit, but it can become a concern if it leads to significantly inadequate calorie or protein intake over extended periods.
Fatigue is reported by a notable proportion of users in real-world data, though it appears less prominently in controlled trial adverse event tables.
One large social-media pharmacovigilance analysis published as a preprint found fatigue was the second most commonly reported symptom after nausea among both semaglutide and tirzepatide users.
Hair thinning and shedding
Hair loss is a side effect worth discussing directly, because it tends to surprise people who were not warned about it. Clinical trial data from SURMOUNT-1 showed alopecia in approximately 5.7% of participants at the highest tirzepatide dose, compared to 1% on placebo.
For semaglutide (Wegovy), the STEP-1 trial reported alopecia in about 3% of participants versus 1% on placebo.
A pharmacovigilance analysis using FDA Adverse Event Reporting System (FAERS) data (Buontempo et al., JEADV 2025) found elevated reporting odds ratios for alopecia with semaglutide (ROR: 2.46, 95% CI: 2.14 to 2.83) and tirzepatide (ROR: 1.73, 95% CI: 1.42 to 2.09). The association was more pronounced with semaglutide in this analysis.
The prevailing explanation is telogen effluvium, a temporary form of diffuse hair shedding that occurs two to four months after a metabolic stressor.
Rapid weight loss (whether from medication, surgery, or any other cause) is a well-established trigger. The shedding is typically reversible once the body adapts and nutrition is adequate.
Injection site reactions
Both medications are administered via subcutaneous injection once weekly. Mild injection site reactions (redness, itching, bruising) have been reported in a small proportion of users.
Rotating injection sites (abdomen, thigh, or upper arm) with each dose is recommended in both prescribing labels.
4. Serious but Rare: Risks You Need to Know About
The side effects below appear rarely in clinical trials (generally below 1%) but are clinically significant enough to require awareness before starting either medication.
| Serious Risk | What It Means | Applies To | Key Guidance |
|---|---|---|---|
| Thyroid C-cell tumours (boxed warning) | Seen in rodent studies at clinically relevant doses; human relevance not established | Both drugs (class-wide) | Avoid if personal or family history of medullary thyroid carcinoma (MTC) or MEN 2 syndrome |
| Acute pancreatitis | Severe upper abdominal pain, sometimes radiating to the back, possibly with vomiting; requires immediate discontinuation | Both drugs (class-wide GLP-1 risk) | Discontinue and seek care if persistent severe abdominal pain develops |
| Acute gallbladder disease | Cholelithiasis reported in 1.6% on Wegovy vs 0.7% on placebo in clinical trials; cholecystitis also reported | Semaglutide (similar risk expected for tirzepatide) | Report upper right abdominal pain to your doctor |
| Acute kidney injury | Primarily from dehydration secondary to GI fluid losses (vomiting, diarrhoea) | Both drugs | Maintain adequate hydration; seek care for persistent vomiting |
| Hypersensitivity reactions | Anaphylaxis and angioedema reported post-marketing (tirzepatide 0.1% in clinical trials) | Both drugs | Discontinue and seek emergency care for signs of allergic reaction |
Sources: FDA prescribing label for Wegovy (semaglutide), accessdata.fda.gov; FDA prescribing label for Zepbound (tirzepatide), accessdata.fda.gov; Alves et al., Frontiers in Endocrinology 2024, PMC8294388.
A note on the thyroid warning
Both prescribing labels carry a boxed warning (the FDA’s most serious category) related to thyroid C-cell tumours observed in rodent studies.
These tumours have not been confirmed in humans, and long-term human data are still accumulating.
The contraindication applies specifically to people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia Type 2.
If that does not apply to you, this warning is more of a monitoring point than an active concern for most patients. Always discuss your personal history with your prescribing doctor before starting either drug.
5. Who Should Not Take These Medications?
The contraindications below apply to both tirzepatide and semaglutide.
They are based on the FDA prescribing labels and are relevant regardless of where you are based, including India, where Mounjaro (tirzepatide) received CDSCO approval for type 2 diabetes in 2024.
| Contraindications (Both Drugs)Personal or family history of medullary thyroid carcinoma (MTC)Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)History of serious hypersensitivity reaction to the drug or any of its excipientsPregnancy (both drugs may cause foetal harm; advise discontinuation at least two months before a planned pregnancy for semaglutide) |
Use with caution (discuss with your doctor) in: a history of pancreatitis; active gallbladder disease; pre-existing gastroparesis; chronic kidney disease; or use of insulin and insulin secretagogues (hypoglycaemia risk increases).
For India-based patients: Mounjaro (tirzepatide, 2.5 mg to 15 mg) is prescription-only and available for the treatment of type 2 diabetes following CDSCO approval. Zepbound (the weight management formulation) is currently undergoing regulatory review. Ozempic (semaglutide for diabetes) is available, and Wegovy (semaglutide for weight management) was expected to launch in India in 2026 by Novo Nordisk.
Always obtain a prescription from a qualified endocrinologist or diabetologist. Neither drug should be obtained or self-administered without medical supervision.
6. How to Manage Side Effects: Practical Strategies
Most GI side effects are temporary, peaking during dose escalation and reducing significantly once you settle at a stable dose.
The strategies below are grounded in clinical guidance and widely used in practice.
Slow down the escalation
Both drugs follow a titration schedule specifically designed to minimise GI intolerance. Tirzepatide starts at 2.5 mg weekly and escalates every four weeks in 2.5 mg increments up to a maximum of 15 mg.
Semaglutide starts at 0.25 mg weekly and escalates over 16 to 20 weeks to 2.4 mg. If you are experiencing significant nausea at a given dose, talk to your prescriber about extending the time at that dose before escalating. Dose reduction is a legitimate and commonly used strategy.
Adjust what and how you eat
Because both drugs slow gastric emptying, large meals sit in your stomach longer and are more likely to trigger nausea. Smaller, more frequent meals work better.
Avoid high-fat, spicy, or very rich foods, especially in the first weeks of treatment. Eating slowly and stopping when you feel full (which happens earlier than usual on these medications) significantly reduces nausea risk.
Manage hydration carefully
Drink fluids between meals rather than during meals, which can worsen the sensation of fullness. If you are experiencing diarrhoea or vomiting, pay careful attention to replacing lost fluids.
Dehydration is one of the more serious downstream risks with both drugs, and it can precipitate acute kidney injury in susceptible individuals.
Protect your protein intake
This matters both for preventing muscle loss during rapid weight reduction and for reducing the risk of hair thinning (telogen effluvium).
Aim to maintain adequate daily protein intake even if your overall appetite is suppressed. Discuss a specific protein target with your doctor or a registered dietitian based on your body weight and activity level.
Sit upright after eating
Lying down after a meal when your gastric emptying is already slowed significantly increases nausea and reflux risk.
Staying upright for at least 30 to 60 minutes after eating can make a meaningful difference, particularly in the early weeks of treatment.
| Symptom | What Helps | When to Call Your Doctor |
|---|---|---|
| Nausea | Smaller meals, low-fat foods, no lying down after eating, slow dose titration | Vomiting lasting more than 24 hours, or inability to keep fluids down |
| Diarrhoea | BRAT-adjacent foods (rice, toast), adequate hydration, avoid high-fibre or spicy triggers | More than 4 to 5 episodes per day, or signs of dehydration |
| Constipation | Increase fluid intake, gentle movement, consider fibre from food first | No bowel movement for more than 3 days, or abdominal bloating with pain |
| Hair shedding | Maintain adequate protein intake, address any micronutrient deficiencies (iron, zinc) | Patchy hair loss (not diffuse shedding), which may suggest a different cause |
| Severe abdominal pain | Do not manage at home | Immediately: could indicate pancreatitis or gallbladder disease |
7. So Which Drug Is Easier on the Body?
Based on available trial data, tirzepatide and semaglutide have broadly similar GI side effect profiles in terms of what symptoms occur. The key differentiator in head-to-head data is the discontinuation rate.
In SURMOUNT-5, significantly more participants stopped semaglutide due to GI intolerance (5.6%) compared to tirzepatide (2.7%). This is a clinically meaningful gap, suggesting tirzepatide may be somewhat better tolerated at the doses tested.
That said, the comparison is not straightforward. Tirzepatide doses in SURMOUNT-5 were escalated to higher maximum doses than semaglutide, and the two drugs have different titration schedules. Individual tolerance varies considerably between patients.
Some people who cannot tolerate semaglutide tolerate tirzepatide well, and vice versa.
The practical conclusion: if you are experiencing significant GI side effects on one drug, switching to the other (after discussion with your doctor) is a reasonable option rather than simply stopping treatment.
| Bottom LineBoth tirzepatide and semaglutide cause GI side effects that are usually mild to moderate and temporary, with symptoms peaking during dose escalation and improving at stable doses.Head-to-head data from SURMOUNT-5 suggest tirzepatide has a lower rate of treatment discontinuation due to GI intolerance (2.7% vs 5.6% for semaglutide), though individual responses vary considerably.Serious risks (pancreatitis, thyroid warnings, gallbladder disease) apply to both drugs. Always obtain a prescription from a qualified doctor and report severe or persistent abdominal pain immediately. |
Frequently Asked Questions
Which has more side effects: tirzepatide or semaglutide?
Both drugs produce a similar range of side effects dominated by nausea, diarrhoea, vomiting, and constipation. In the SURMOUNT-5 head-to-head trial, GI adverse events were the most common in both groups.
However, fewer people discontinued tirzepatide due to GI side effects (2.7%) compared to semaglutide (5.6%), suggesting tirzepatide may be marginally better tolerated at the doses used in that trial.
Are nausea and GI side effects worse on Mounjaro or Ozempic?
In the SURPASS-2 trial (tirzepatide vs semaglutide 1 mg for type 2 diabetes), nausea rates were broadly comparable: 17% to 22% for tirzepatide doses versus 18% for semaglutide.
The important variable is that tirzepatide is often used at higher doses (up to 15 mg) than semaglutide (max 1 mg for the Ozempic/diabetes formulation), which may influence the overall symptom burden in real-world use.
At equivalent therapeutic doses, the two drugs are broadly comparable for GI tolerability.
How long does nausea last on these medications?
Nausea is most pronounced during dose escalation, typically in the first four to eight weeks at a new dose level.
For most people, it improves substantially once they stabilize at a maintenance dose. A 2026 review published in Frontiers in Endocrinology noted that approximately 60% to 70% of patients can titrate to full therapeutic doses with minimal GI difficulty.
Can these drugs cause hair loss?
Yes, hair shedding (telogen effluvium) has been reported with both drugs.
Alopecia was reported in about 5.7% of tirzepatide users at the highest dose in SURMOUNT-1 and about 3% of semaglutide users in the Wegovy trials. The prevailing view among researchers is that this is primarily driven by rapid weight loss rather than by the medication itself. Maintaining adequate protein and micronutrient intake helps reduce the risk.
Is tirzepatide available in India, and are the side effects the same?
Mounjaro (tirzepatide) received CDSCO approval in India for the treatment of type 2 diabetes in 2024. It is a prescription-only medication.
The side effect profile in India is the same as in global clinical trials, as the drug’s mechanism and formulation are identical.
Wegovy (semaglutide for weight management) was under consideration for India launch as of 2026. Always consult a qualified endocrinologist or diabetologist before starting either drug.
| Medical DisclaimerThis article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting, changing, or stopping any medication. Information is based on published clinical trials and FDA prescribing labels available as of May 2026. |
